Uniqure (QURE) Upgraded by BidaskClub to “Strong-Buy”
BidaskClub upgraded shares of Uniqure (NASDAQ:QURE) from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday morning.
Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald restated a buy rating and issued a $65.00 target price on shares of Uniqure in a report on Thursday, November 15th. HC Wainwright set a $48.00 price target on Uniqure and gave the company a buy rating in a report on Thursday, November 15th. B. Riley began coverage on Uniqure in a report on Monday, December 31st. They set a buy rating and a $72.00 price target on the stock. Guggenheim began coverage on Uniqure in a report on Monday, December 17th. They set a buy rating and a $35.00 price target on the stock. Finally, Chardan Capital reiterated a buy rating and set a $70.00 price target on shares of Uniqure in a report on Monday, December 3rd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $68.70.
Shares of NASDAQ QURE opened at $63.35 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.85 and a current ratio of 11.85. The firm has a market capitalization of $2.44 billion, a P/E ratio of -27.07 and a beta of 1.07. Uniqure has a 52-week low of $20.29 and a 52-week high of $67.93.
In other news, CEO Matthew C. Kapusta sold 67,376 shares of Uniqure stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $63.96, for a total transaction of $4,309,368.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Christian Klemt sold 5,739 shares of Uniqure stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $27.91, for a total value of $160,175.49. Following the transaction, the insider now owns 40,000 shares in the company, valued at approximately $1,116,400. The disclosure for this sale can be found here. Insiders have sold 113,390 shares of company stock worth $5,764,148 in the last quarter. 1.56% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of QURE. Legal & General Group Plc grew its stake in Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 700 shares in the last quarter. Exane Derivatives purchased a new position in Uniqure in the fourth quarter valued at about $41,000. Advisor Group Inc. grew its stake in Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares in the last quarter. HRT Financial LLC purchased a new position in Uniqure in the fourth quarter valued at about $289,000. Finally, Financial Gravity Companies Inc. purchased a new position in Uniqure in the fourth quarter valued at about $310,000. Institutional investors and hedge funds own 61.16% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
See Also: What is the float in trading stocks?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.